deltatrials
Recruiting PHASE1 INTERVENTIONAL 5-arm NCT07128797

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Subcutaneous Injections of B1344 Injection in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

Sponsor: Tasly Biopharmaceuticals Co., Ltd.

Conditions NAFLD (Non-alcoholic Fatty Liver Disease) NASH (Nonalcoholic Steatohepatitis)
Interventions B1344 Placebo
Updated 1 time since 2025 Last updated: Aug 18, 2025 Started: Jul 24, 2025 Primary completion: Jun 30, 2026 Completion: Jul 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07128797, this PHASE1 trial focuses on NAFLD (Non-alcoholic Fatty Liver Disease) and NASH (Nonalcoholic Steatohepatitis) and remains actively recruiting participants. Sponsored by Tasly Biopharmaceuticals Co., Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Sep 2025 – present · 10 months · monthly snapshotRecruiting

Change History

1 version recorded
Recruiting — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tasly Biopharmaceuticals Co., Ltd.
Data source: Tasly Biopharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations